Science
Espervita Therapeutics is focused on the discovery of metabolic reprogramming therapies, with a lead program developing first-in-class liver- and kidney-specific acetyl-CoA metabolic enzyme inhibitors.
Acetyl-CoA Metabolic Enzymes
Acetyl-CoA links carbohydrate and fat metabolism and serves as a primary building block for fatty acids, triglycerides, and cholesterol. Aberrant production and utilization of acetyl-CoA is a driver of metabolic-dysfunction associated steatohepatitis (MASH), chronic kidney disease (CKD), and fibrotic remodeling in the liver and kidney. Espervita's lead compound, EVT0185, is a first-in-class, liver- and kidney-selective inhibitor of acetyl-CoA metabolic enzymes that demonstrates broad efficacy in preclinical models—lowering blood glucose and lipid synthesis, reversing MASH and liver fibrosis, preserving kidney function, and decreasing HCC tumor burden.
Espervita’s EVT0185 Shows Dramatic Tumor Reduction and Immune Activation in Preclinical MASH-Driven Hepatocellular Carcinoma
July 30, 2025
Espervita’s EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication
January 6, 2026